Gomez, Carmen Elena and Najera, Jose Luis and Jimenez, Eva Perez and Jimenez, Victoria and Wagner, Ralf and Graf, Marcus and Frachette, Marie-Joelle and Liljestrom, Peter and Pantaleo, Giuseppe and Esteban, Mariano (2007) Head-to-head comparison on the immunogenicity of two HIV/AIDS vaccine candidates based on the attenuated poxvirus strains MVA and NYVAC co-expressing in a single locus the HIV-1(BX08) gp120 and HIV-1(IIIB) Gag-Pol-Nef proteins of clade B. VACCINE, 25 (15). pp. 2863-2885. ISSN 0264-410X, 1873-2518
Full text not available from this repository. (Request a copy)Abstract
In this investigation we have generated and defined the immunogenicity of two novel HIV/AIDS vaccine candidates based on the highly attenuated vaccinia virus strains, MVA and NYVAC, efficiently expressing in the same locus (TK) and under the same viral promoter the codon optimized HIV-1 genes encoding gp120 and Gag-Pol-Nef antigens of clade B (referred as MVA-B and NYVAC-B). In infected human HeLa cells, gp120 is released from cells and GPN is produced as a polyprotein; NYVAC-B induces severe apoptosis but not MVA-B. The two poxvirus vectors showed genetic stability of the inserts. In BALB/c and in transgenic HHD mice for human HLA-A2 class 1, both vectors are efficient immunogens and induced broad cellular immune responses against peptides represented in the four HIV-1 antigens. Some difference, were observed in the magnitude and breadth of the immune response in the Mouse models. In DNA prime/poxvirus boost protocols, the strongest immune response, as measured by fresh IFN-gamma and IL-2 ELISPOT, was obtained in BALB/c mice boosted with NYVAC-B, while in HHD mice there were no differences between the poxvirus vectors. When the prime/boost was performed with homologous or with combination of poxvirus vectors, the protocols MVA-B/MVA-B and NYVAC-B/NYVAC-B, or the combination NYVAC-B/MVA-B gave the most consistent broader immune response in both mouse models, although the magnitude of the overall response was higher for the DNA-B/poxvirus-B regime. All of the immunization protocols induced some Immoral response against the gp160 protein from HIV-1 clone LAV. Our findings indicate that MVA-B and NYVAC-B meet the criteria to be potentially useful vaccine candidates against HIV/AIDS. (c) 2006 Elsevier Ltd. All rights reserved.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | CELL IMMUNE-RESPONSES; VIRUS ANKARA; ENVELOPE GLYCOPROTEIN; MUCOSAL CHALLENGE; VIRAL VECTORS; BOOST VACCINE; IFN-GAMMA; DNA; AIDS; IMMUNIZATION; HIV/AIDS; clade B vaccine; poxvirus vectors; MVA; NYVAC; immune response; mouse models |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Medizinische Mikrobiologie und Hygiene |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 14 Dec 2020 13:30 |
| Last Modified: | 14 Dec 2020 13:30 |
| URI: | https://pred.uni-regensburg.de/id/eprint/32891 |
Actions (login required)
 |
View Item |
